A Phase 1, Open-Label, Dose-Escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-Positive Refractory/Relapsed Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2012
At a glance
- Drugs MDX 1401 (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 02 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jun 2009 Planned end date changed from 1 Aug 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 26 Mar 2009 Interim results will be presented at the American Association for Cancer Research annual meeting (AACR-2009).